Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: A report from the Children'S Oncology Group

Wanda L. Salzer, Naomi J. Winick, Pierre Wacker, Xiaomin Lu, Meenakshi Devidas, Jonathan J. Shuster, Donald H. Mahoney, Stephen J. Lauer, Bruce M. Camitta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Plasma steady state methotrexate (MTX) level and red blood cell (RBC) MTX and folate concentrations were evaluated in 1124 children with newly diagnosed acute lymphoblastic leukemia enrolled in the Pediatric Oncology Group studies 9005 (lower risk; Regimens A and C) and 9006 (higher risk; Regimen A). These regimens included intermediate-dose MTX (1 g/m) given as a 24 hours infusion every other week for 12 doses during intensification. Plasma MTX level was evaluated at the end of MTX infusions. RBC MTX and folate concentrations were measured at the end of intensification. The 5 year continuous complete remission was 76±1.4% versus 85±3.0% for those patients with steady state MTX levels less than or equal to and greater than 14 μM, respectively (P=0.0125). Hispanic children had significantly reduced median steady state MTX levels, 8.7 μM, compared with non-Hispanic children, 9.95 μM (P=0.0015), but this did not correlate with a difference in outcome. Neither RBC MTX, RBC folate, nor the RBC MTX:folate ratio identified children at increased risk of failure.

Original languageEnglish (US)
JournalJournal of Pediatric Hematology/Oncology
Volume34
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Folic Acid
Methotrexate
Erythrocytes
Hispanic Americans
Pediatrics

Keywords

  • childhood acute lymphoblastic leukemia
  • methotrexate metabolism
  • red blood cell
  • red blood cell methotrexate and folate

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia : A report from the Children'S Oncology Group. / Salzer, Wanda L.; Winick, Naomi J.; Wacker, Pierre; Lu, Xiaomin; Devidas, Meenakshi; Shuster, Jonathan J.; Mahoney, Donald H.; Lauer, Stephen J.; Camitta, Bruce M.

In: Journal of Pediatric Hematology/Oncology, Vol. 34, No. 1, 01.2012.

Research output: Contribution to journalArticle

Salzer, Wanda L. ; Winick, Naomi J. ; Wacker, Pierre ; Lu, Xiaomin ; Devidas, Meenakshi ; Shuster, Jonathan J. ; Mahoney, Donald H. ; Lauer, Stephen J. ; Camitta, Bruce M. / Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia : A report from the Children'S Oncology Group. In: Journal of Pediatric Hematology/Oncology. 2012 ; Vol. 34, No. 1.
@article{3301596d352441f7a1ba6401a5b2f995,
title = "Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: A report from the Children'S Oncology Group",
abstract = "Plasma steady state methotrexate (MTX) level and red blood cell (RBC) MTX and folate concentrations were evaluated in 1124 children with newly diagnosed acute lymphoblastic leukemia enrolled in the Pediatric Oncology Group studies 9005 (lower risk; Regimens A and C) and 9006 (higher risk; Regimen A). These regimens included intermediate-dose MTX (1 g/m) given as a 24 hours infusion every other week for 12 doses during intensification. Plasma MTX level was evaluated at the end of MTX infusions. RBC MTX and folate concentrations were measured at the end of intensification. The 5 year continuous complete remission was 76±1.4{\%} versus 85±3.0{\%} for those patients with steady state MTX levels less than or equal to and greater than 14 μM, respectively (P=0.0125). Hispanic children had significantly reduced median steady state MTX levels, 8.7 μM, compared with non-Hispanic children, 9.95 μM (P=0.0015), but this did not correlate with a difference in outcome. Neither RBC MTX, RBC folate, nor the RBC MTX:folate ratio identified children at increased risk of failure.",
keywords = "childhood acute lymphoblastic leukemia, methotrexate metabolism, red blood cell, red blood cell methotrexate and folate",
author = "Salzer, {Wanda L.} and Winick, {Naomi J.} and Pierre Wacker and Xiaomin Lu and Meenakshi Devidas and Shuster, {Jonathan J.} and Mahoney, {Donald H.} and Lauer, {Stephen J.} and Camitta, {Bruce M.}",
year = "2012",
month = "1",
doi = "10.1097/MPH.0b013e31820ee239",
language = "English (US)",
volume = "34",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia

T2 - A report from the Children'S Oncology Group

AU - Salzer, Wanda L.

AU - Winick, Naomi J.

AU - Wacker, Pierre

AU - Lu, Xiaomin

AU - Devidas, Meenakshi

AU - Shuster, Jonathan J.

AU - Mahoney, Donald H.

AU - Lauer, Stephen J.

AU - Camitta, Bruce M.

PY - 2012/1

Y1 - 2012/1

N2 - Plasma steady state methotrexate (MTX) level and red blood cell (RBC) MTX and folate concentrations were evaluated in 1124 children with newly diagnosed acute lymphoblastic leukemia enrolled in the Pediatric Oncology Group studies 9005 (lower risk; Regimens A and C) and 9006 (higher risk; Regimen A). These regimens included intermediate-dose MTX (1 g/m) given as a 24 hours infusion every other week for 12 doses during intensification. Plasma MTX level was evaluated at the end of MTX infusions. RBC MTX and folate concentrations were measured at the end of intensification. The 5 year continuous complete remission was 76±1.4% versus 85±3.0% for those patients with steady state MTX levels less than or equal to and greater than 14 μM, respectively (P=0.0125). Hispanic children had significantly reduced median steady state MTX levels, 8.7 μM, compared with non-Hispanic children, 9.95 μM (P=0.0015), but this did not correlate with a difference in outcome. Neither RBC MTX, RBC folate, nor the RBC MTX:folate ratio identified children at increased risk of failure.

AB - Plasma steady state methotrexate (MTX) level and red blood cell (RBC) MTX and folate concentrations were evaluated in 1124 children with newly diagnosed acute lymphoblastic leukemia enrolled in the Pediatric Oncology Group studies 9005 (lower risk; Regimens A and C) and 9006 (higher risk; Regimen A). These regimens included intermediate-dose MTX (1 g/m) given as a 24 hours infusion every other week for 12 doses during intensification. Plasma MTX level was evaluated at the end of MTX infusions. RBC MTX and folate concentrations were measured at the end of intensification. The 5 year continuous complete remission was 76±1.4% versus 85±3.0% for those patients with steady state MTX levels less than or equal to and greater than 14 μM, respectively (P=0.0125). Hispanic children had significantly reduced median steady state MTX levels, 8.7 μM, compared with non-Hispanic children, 9.95 μM (P=0.0015), but this did not correlate with a difference in outcome. Neither RBC MTX, RBC folate, nor the RBC MTX:folate ratio identified children at increased risk of failure.

KW - childhood acute lymphoblastic leukemia

KW - methotrexate metabolism

KW - red blood cell

KW - red blood cell methotrexate and folate

UR - http://www.scopus.com/inward/record.url?scp=84855460266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855460266&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e31820ee239

DO - 10.1097/MPH.0b013e31820ee239

M3 - Article

C2 - 21364468

AN - SCOPUS:84855460266

VL - 34

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 1

ER -